Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia

Medical Oncology

Volumn 23, Issue 1, 2006, Pages 137-139

  Lundin, Jeanette ^a   Karlsson, Claes ^a   Celsing, Fredrik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alemtuzumab; Anemia; B CLL; Campath; Hemolysis

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; PREDNISONE; VALACICLOVIR;

AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BONE MARROW BIOPSY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, B-CELL, CHRONIC;

EID: 33646893484     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:1:137     Document Type: Article

References (27)

1. Engelfriet CP, Overbeeke MA, von dem Borne AE. Autoimmune hemolytic anemia. Semin Hematol 1992;29:3-12.
2. Rodon P, Breton P, Courouble G. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H. Eur J Haematol 2003;70:319-321.
3. Bastion Y, Coiffier B, Dumontet C, Espinouse D, Bryon PA. Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 1992;3:171-172.
4. Weiss RB, Freiman J, Kweder SL, Diehl LF, Byrd JC. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998;16:1885-1889.
5. Juliusson G. Complications in the treatment of B-CLL with purine analogues. Hematol Cell Ther 1997;39(Suppl 1):S41-44.
6. Catovsky D, Richards S. Incidence of hemolytic anemia after chemotherapy in the B-CLL4 trial. A possible protective role for fludarabine plus cyclophosphamide. Blood 2004;104:Abstract 480.
7. Efremov DG, et al. Restricted immunoglobulin VH region repertoire in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. Blood 1996;87:3869-3876.
8. Pritsch O, Maloum K, Dighiero G. Basic biology of autoimmune phenomena in chronic lymphocytic leukemia. Semin Oncol 1998;25:34-41.
9. Collins PW, Newland AC. Treatment modalities of autoimmune blood disorders. Semin Hematol 1992;29:64-74.
10. Treumann A, Lifely MR, Schneider P, Ferguson MA. Primary structure of CD52. J Biol Chem 1995;270:6088-6099.
11. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993;82:807-812.
12. Osterborg A, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997;15:1567-1574.
13. McCune SL, et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma 2002;43:1007-1011.
14. Rai KR, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891-3897.
15. Keating MJ, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43:1755-1762.
16. Österborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996;93:151-153.
17. Lundin J, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-773.
18. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-327.
19. Dyer MJ, Hale G, Hayhoe FG, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989;73:1431-1439.
20. Kirchhoff C, Hale G. Cell-to-cell transfer of glycosylphosphatid/ linositol-anchored membrane proteins during sperm maturation. Mol Hum Reprod 1996;2:177-184.
21. Heit W, et al. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. Br J Haematol 1986;64:479-486.
22. Mone A, Cheney C, Lin TS, Jefferson S, Byrd JC. Campath-1H induced caspase-independent apoptosis in primary human chronic lymphocytic leukemia cells through a cytoskeletal dependent mechanism. Blood 2003;102:Abstract 1588.
23. Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998;95:427-436.
24. Willis F, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001;114:891-898.
25. Ru X, Liebman HA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol 2003;123:278-281.
26. Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998;25:80-97.
27. Mauro FR, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000;95:2786-2792.